Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very ...

Healthcare may not lead the next market rally, but current levels offer compelling risk/reward for contrarian investors ...

The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same ...

A second magnificent ultra-high-yield dividend stock that's begging to be bought in November is pharmaceutical titan Pfizer ( ...

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions. Merck has a 3.7% yield and a lot of leeway to protect its dividend. Some of the largest drugmakers in ...

You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...